News

Important Information for MacroGenics, Inc. Investors

Important Information for MacroGenics, Inc. Investors

Important Updates for MacroGenics, Inc. Investors

Attention, shareholders of MacroGenics, Inc. (NASDAQ: MGNX). If you've experienced financial losses related to your investments in this company, there are crucial updates and opportunities you should consider.

Overview of the Class Action

Investors who acquired shares of MGNX during the designated class period are encouraged to reach out to a law firm that specializes in class actions. While it’s not necessary to be appointed as the lead plaintiff to recover losses, participating in this legal process may prove advantageous.

Class Period Details

The class period for this action runs from March 7, 2024, to May 9, 2024. During this timeframe, serious concerns arose regarding the safety data from the TAMARACK Phase 2 study of the drug vobramitamab duocarmazine. On May 9, 2024, alarming information about the drug’s safety was revealed, resulting in a significant decline in MGNX's stock price, which plummeted by 77.4% or $11.36 per share.

Crucial Deadlines

Shareholders must act quickly, as the deadline to register for this class action is September 24, 2024. It’s vital to register in order to secure your status as a shareholder during this period.

Your Next Steps as a Shareholder

Once you register, participants will gain access to portfolio monitoring software that offers ongoing updates about the case. This is an effective way to stay informed about developments as the legal action progresses.

Why Choose The Gross Law Firm?

The Gross Law Firm is committed to protecting the interests of investors. The firm diligently works to hold companies accountable for any fraudulent activities or misleading communications that could adversely affect stock value. Their goal is to help recover losses incurred by shareholders due to damaging misinformation.

Contact Information for Investors

If you need further clarification or wish to initiate a claim, you can contact The Gross Law Firm:

Address:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903

Frequently Asked Questions

What is the purpose of the class action?

The class action aims to assist shareholders in recovering losses caused by misleading information regarding MacroGenics, Inc.

How do I know if I'm eligible to join the class action?

If you purchased shares of MacroGenics between March 7, 2024, and May 9, 2024, you may qualify to participate.

What happens after I register?

After registration, you will receive updates and be monitored throughout the litigation process until it concludes.

Is there any cost to join the class action?

No, there are no costs or obligations to participate in this case.

Who will represent the shareholders?

The Gross Law Firm will represent the class action, utilizing their expertise and commitment to investor protection.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Squalane in K-Beauty: Revolutionizing Skin Care Routines

Updated Category News Views 114

The Spotlight's on Squalane in K-Beauty Korean beauty trends are usually at the pulse of global skincare, and if you’ve been watching, there’s a new kid making waves: squalane. Now, before you wrinkle your brow wondering why this old-timer's getting all the love, let me break it down. Squalane is adding a new sheen to K-beauty’s obsession with hydration and skin...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 93

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
Lemon Grove Bans Bird Sales to Combat Cruelty

Updated Category News Views 95

A Bird's Eye View on Lemon Grove's Bold Stand The folks in Lemon Grove, California, just sent out a loud and clear message: put an end to the inhumane sale of birds in pet stores. With 65% of voters backing Measure E, they've decided that birds fly best when they aren't part of a retail circus. Under this new rule, stores can only put birds up for adoption if they're...

Continue Reading
RSPO RT2026 Tackles Indonesian Fires and Export Shifts

Updated Category News Views 42

Indonesia's Burning Questions There's been a lot of smoke—literally and figuratively—hanging over the palm oil industry in Indonesia this year. At the RSPO's Annual Roundtable on Sustainable Palm Oil (RT2026), attendees didn't shy away from addressing the harsh realities. In a year marked by rampant fires, thanks to the blistering El Niño, the RSPO showcased data...

Continue Reading
Healthcare Consulting Market Hits $56.99B by 2031

Updated Category News Views 70

Market Set to Boom: $56.99 Billion by 2031 Grab your coffee and take a seat—this isn't your usual healthcare spiel. The healthcare consulting services market's cruising down a rapid growth highway, projected to tap dance to a whopping $56.99 billion by 2031, starting from $35.55 billion last year. We're talking a solid 9.9% CAGR, folks. Now, anytime numbers stack this...

Continue Reading
Qfin Faces Stock Lawsuit: Know Your Investor Rights

Updated Category News Views 6

Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...

Continue Reading
MRP Securities Fraud: Investors Eye Millrose Case

Updated Category News Views 144

Millrose's Troubles: A Closer Look at the Fraud Accusation Now, here's a pickle. Millrose Properties, Inc. (NYSE: MRP) has landed itself in hot water. We've got a bona fide class action lawsuit on our hands, and Schall, Brown & Schwartz LLP is waving the flag, rallying investors to step up and face the music. Turns out the company's talk might not have walked the walk...

Continue Reading
Q32 Bio Eyes New Horizons with Bempikibart's Potentials

Updated Category News Views 77

Q32 Bio Steers Forward: New Insights from Chief Results Today's update isn't just another quarterly snooze-fest—it’s a nudge in a crucial direction for Q32 Bio (NASDAQ:QTTB). After a bold brush with the European Academy of Dermatology and Venereology (EADV) Congress 2026, the company laid out a plan and a half, showing its hand with bempikibart for alopecia areata...

Continue Reading
Amdocs Shares Plunge Over T-Mobile Legal Clash

Updated Category News Views 38

Nothing like waking up to the smell of lawsuits, huh? That's what Amdocs Limited (NASDAQ: DOX) investors were hit with on the morning of November 4, 2026. Watching nearly a third of your stock's value evaporate overnight—ouch. This all happened because of a classic corporate slugfest with none other than T-Mobile. Now, they're slugging it out over a supposedly...

Continue Reading
Samsung Ups Stake in TCL CSOT: A Game-Changer?

Updated Category News Views 137

Samsung Electronics' Strategic Play Sometimes it takes a gutsy move to shake up the industry, and Samsung Electronics just went for it. Snagging a 10.16% stake in TCL CSOT isn't just some run-of-the-mill acquisition. It's a calculated chess piece placement in the cutthroat display tech arena. Unpacking the Stake Game This latest move shifts Samsung Display's stake to...

Continue Reading

Top 5 Most Recently Viewed Articles

Alex Bastian Named VP of Commercial Strategy at Memo Therapeutics

Updated Category News Views 282

Alex Bastian Appointed as VP of Commercial Strategy at Memo Therapeutics AG Memo Therapeutics AG (or “MTx”), a late-stage biotech firm committed to transforming unique human immune responses into effective treatments for viral infections and cancer, has announced the appointment of Alex Bastian as its new VP of Commercial Strategy. Expertise in the Biotech Industry...

Continue Reading
Understanding Alliant Energy's Rising Short Interest Insights

Updated Category News Views 282

Alliant Energy's Rising Short Interest Alliant Energy's short percent of float has recently increased, reaching 9.49% since the last report. The energy provider has reported a total of 7.74 million shares sold short. This accounts for about 3.46% of its total available shares for trading, indicating an active trading environment. Understanding Short Interest Short...

Continue Reading
China's 2024 Fiscal Revenue: A Shift Towards Proactive Measures

Updated Category News Views 270

China's Fiscal Revenue Growth and Economic Challenges In recent reports, it's shown that China's fiscal revenue in 2024 has seen an increase of 1.3% year on year. This rate of growth is a significant decline from the 6.4% expansion recorded in 2023. The slowdown in revenue has raised concerns amid economic uncertainties. The Impact of the Property Market One of the...

Continue Reading
Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health

Updated Category News Views 542

Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health In a significant step forward for youth mental health advocacy, Bill Brady, the CEO of Troomi Wireless, has been appointed to the Board of Directors of Speak Our Minds, a nonprofit organization dedicated to combatting the youth mental health crisis. This collaboration aims to unite technology with a...

Continue Reading
Investigation of Investors' Claims Against Unisys Corporation

Updated Category News Views 467

Rosen Law Firm Investigates Claims for Unisys Corporation Investors Rosen Law Firm, a well-respected global investor rights organization, is currently conducting an investigation concerning potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: UIS). This investigation arises from serious allegations suggesting that Unisys might have provided...

Continue Reading